Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

SEDA Experts LLC, a leading expert witness firm providing world-class financial expert witness services, announced today that ...

Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain ...

With a market cap of $145.7 billion, Pfizer Inc. (PFE) is a global, research-driven biopharmaceutical company, specializing in the discovery, development, and commercialization of innovative medicines ...

“In the Gulf, we are committed to accelerating the availability of global innovations while fostering partnerships with governments, healthcare providers, and key stakeholders,” Serhat ...

Pfizer is extending its partnership with medtech company CytoReason to use CytoReason’s artificial intelligence in the drug discovery process. As part of the partnership, Pfizer will make a $20 ...

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

Article ‘Count’ and ‘Share’ for Pfizer Global Research & Development, France based on listed parameters only. The articles listed below published by authors from Pfizer Global Research ...

Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets Decision comes two years after acquiring the drug’s parent company, Global Blood Therapeutic, in a $5.4 billion deal By ...

Pfizer Pharmaceuticals Global B.V., Netherlands Time frame: 1 May 2023 - 30 April 2024 Research. Overall research output. Count ...